NeuroSense Therapeutics Total Asset vs. Current Ratio
| NRSNW Stock | USD 0.25 0.13 34.21% |
NeuroSense Therapeutics Total Assets |
|
For NeuroSense Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NeuroSense Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NeuroSense Therapeutics Ltd utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NeuroSense Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NeuroSense Therapeutics Ltd over time as well as its relative position and ranking within its peers.
NeuroSense |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuroSense Therapeutics. If investors know NeuroSense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuroSense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of NeuroSense Therapeutics is measured differently than its book value, which is the value of NeuroSense that is recorded on the company's balance sheet. Investors also form their own opinion of NeuroSense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is NeuroSense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuroSense Therapeutics' market value can be influenced by many factors that don't directly affect NeuroSense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuroSense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuroSense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuroSense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
NeuroSense Therapeutics Current Ratio vs. Total Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NeuroSense Therapeutics's current stock value. Our valuation model uses many indicators to compare NeuroSense Therapeutics value to that of its competitors to determine the firm's financial worth. NeuroSense Therapeutics Ltd is regarded fifth in total asset category among its peers. It is regarded third in current ratio category among its peers . The ratio of Total Asset to Current Ratio for NeuroSense Therapeutics Ltd is about 393,069 . At this time, NeuroSense Therapeutics' Total Assets are fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value NeuroSense Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.NeuroSense Current Ratio vs. Total Asset
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
NeuroSense Therapeutics |
| = | 3.18 M |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
NeuroSense Therapeutics |
| = | 8.08 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
NeuroSense Current Ratio Comparison
NeuroSense Therapeutics is currently under evaluation in current ratio category among its peers.
NeuroSense Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NeuroSense Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NeuroSense Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of NeuroSense Therapeutics' change in net profit over the period of time. It can combine multiple indicators of NeuroSense Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 30.2 M | 18 M | |
| Net Interest Income | -372 K | -390.6 K | |
| Interest Income | 178 K | 186.9 K | |
| Operating Income | -12 M | -11.4 M | |
| Net Loss | -11.3 M | -10.7 M | |
| Income Before Tax | -11.3 M | -10.7 M | |
| Total Other Income Expense Net | 769 K | 792 K | |
| Net Loss | -11.3 M | -10.7 M | |
| Income Tax Expense | (1.00) | (1.05) | |
| Net Loss | (0.74) | (0.78) | |
| Income Quality | 0.75 | 0.39 | |
| Net Income Per E B T | 0.90 | 0.98 |
NeuroSense Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NeuroSense Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NeuroSense Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NeuroSense Therapeutics' important profitability drivers and their relationship over time.
Use NeuroSense Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeuroSense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeuroSense Therapeutics will appreciate offsetting losses from the drop in the long position's value.NeuroSense Therapeutics Pair Trading
NeuroSense Therapeutics Ltd Pair Trading Analysis
The ability to find closely correlated positions to NeuroSense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeuroSense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeuroSense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeuroSense Therapeutics Ltd to buy it.
The correlation of NeuroSense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeuroSense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeuroSense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeuroSense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your NeuroSense Therapeutics position
In addition to having NeuroSense Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Information Technology ETFs Thematic Idea Now
Information Technology ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Information Technology ETFs theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Information Technology ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.